Biodesix Using VeriStrat to Evaluate Kadmon's Tyrosine Kinase Inhibitor
February 27, 2012
Biodesix Using VeriStrat to Evaluate Kadmon's Tyrosine Kinase Inhibitor
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Biodesix Inks Deal with Bruker for Mass Spec Support; Closes on $8.8M in Series D Financing
April 11, 2013 / GenomeWeb Daily News - Biodesix IDs Proteomic Signature for Predicting Response to GlobeImmune Pancreatic Cancer Therapy
June 29, 2012 / ProteoMonitor - Biodesix Inks Deal to Test Veristrat in Phase III Clinical Trial for Kadmon Lung Cancer Drug
March 2, 2012 / ProteoMonitor - Biodesix Publishes Study Indicating Significant Influence of Veristrat on Doctor Treatment Decisions
April 5, 2013 / ProteoMonitor - Study Suggests Biodesix's Veristrat Can Identify NSCLC Responders to Erlotinib, Gemcitabine
September 7, 2012 / ProteoMonitor